RenovoRx Reports Third-Quarter 2026 Revenue of $1.07 Million
Revenue rose from $266,000 a year earlier. RenovoRx maintained 2026 revenue guidance of $3.75 million to $4.25 million and said cash resources should fund operations into the second half of 2027. Active cancer center customers increased to 26 from 21 at the end of the second quarter.
RenovoRx reported third-quarter 2026 revenue of $1.07 million, a significant increase from $266,000 in the same period of 2025. The company maintained its full-year 2026 revenue guidance of $3.75 million to $4.25 million and stated that its current cash resources are sufficient to fund operations into the second half of 2027. Commercial momentum continued with the number of active cancer center customers rising to 26, up from 21 at the end of the second quarter. On the clinical front, the company confirmed that its Phase III TIGeR-PaC trial reached full enrollment in August, with initial top-line data expected in the second half of 2027.
Additionally, the company noted the first commercial clinical use of its TAMP platform for a solid tumor beyond pancreatic cancer.